TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
XLO

Xilio Development Inc

Healthcare · Biotechnology

8.20$ -2.7% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns Xilio Development Inc (XLO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 51.7% of the shares are freely tradable; institutional investors hold 51.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 51.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 28.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 51.7%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 6.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 7Mio.

Largest Shareholders

Institutions

Institutions XLO
Name Stake (%) Shares Change (%) Date
Bain Capital Life Sciences Investors, LLC 10.09 664,021 +0.0 06/30/2026
Orbimed Advisors LLC 9.00 592,300 +0.0 06/30/2026
Frazier Life Sciences Management, L.P. 6.42 422,505 +0.0 06/30/2026
Stonepine Capital Management Llc 3.43 225,994 +252.2 06/30/2026
Vanguard Capital Management, LLC 2.71 178,517 +44.4 06/30/2026
Sio Capital Management, LLC 2.32 152,464 +0.0 06/30/2026
Adage Capital Partners Gp LLC 1.70 111,541 +0.0 06/30/2026
Merck & Co Inc 1.61 105,982 +0.0 06/30/2026
Renaissance Technologies Corp 0.97 64,153 +29.4 06/30/2026

Funds

Funds XLO
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.16 142,440 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?